Comment on

• Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies).

  Bosch X, Rovira M, Sitges M, Domènech A, Ortiz-Pérez JT, de Caralt TM, Morales-Ruiz M, Perea RJ, Monzó M, Esteve J. Bosch X, et al. J Am Coll Cardiol. 2013 Jun 11;61(23):2355-62. doi: 10.1016/j.jacc.2013.02.072. Epub 2013 Apr 10. J Am Coll Cardiol. 2013. PMID: 23583763 Clinical Trial.
• Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction.

  Spallarossa P, Guerrini M, Arboscello E, Sicbaldi V. Spallarossa P, et al. J Am Coll Cardiol. 2013 Dec 24;62(25):2451-2452. doi: 10.1016/j.jacc.2013.07.077. Epub 2013 Sep 4. J Am Coll Cardiol. 2013. PMID: 24013048 No abstract available.
• Enalapril/carvedilol for prevention of chemotherapy-induced heart failure: an end to the problem.

  Golwala H. Golwala H. J Am Coll Cardiol. 2013 Dec 24;62(25):2450-2451. doi: 10.1016/j.jacc.2013.06.059. Epub 2013 Sep 4. J Am Coll Cardiol. 2013. PMID: 24013049 No abstract available.